

Priya Nair
Paul Lee
Claire Reynolds
Nguyen Dinh Nguyen
John Myburgh
John A. Eisman
Jacqueline R. Center

Significant perturbation of vitamin D–parathyroid–calcium axis and adverse clinical outcomes in critically ill patients

Received: 9 January 2012
Accepted: 9 September 2012
Published online: 13 October 2012
© Springer-Verlag Berlin Heidelberg and ESICM 2012

Electronic supplementary material

The online version of this article (doi:[10.1007/s00134-012-2713-y](https://doi.org/10.1007/s00134-012-2713-y)) contains supplementary material, which is available to authorized users.

P. Nair (✉) · C. Reynolds
Intensive Care Unit, St Vincents Hospital,
Victoria Street, Darlinghurst, Sydney,
Australia
e-mail: pnair@stvincents.com.au
Tel.: +61-2-83823611
Fax: +61-2-83823947

P. Nair · P. Lee · N. D. Nguyen ·
J. A. Eisman · J. R. Center
Bone and Mineral Research Programme,
Garvan Institute of Medical Research,
Victoria Street, Darlinghurst, Sydney,
Australia

J. Myburgh · J. A. Eisman · J. R. Center
Faculty of Medicine, University of New
South Wales, Sydney, Australia

P. Lee
Department of Diabetes and Endocrinology,
Princess Alexandra Hospital, Brisbane,
Australia

P. Lee
School of Medicine, University of
Queensland, Brisbane, Australia

P. Nair · J. Myburgh
Critical Care and Trauma Division, The
George Institute for Global Health, Sydney,
Australia

J. Myburgh
Intensive Care Unit, St George Hospital,
Kogarah, Sydney, Australia

J. A. Eisman · J. R. Center
Department of Endocrinology, St Vincents
Hospital, Victoria Street, Darlinghurst,
Sydney, Australia

Abstract Purpose: A prospective multicentre cohort study was conducted to determine the prevalence of hypovitaminosis D in adult critically ill patients, to characterize alterations in the parathyroid hormone (PTH)–vitamin D–calcium axis and to explore associations between hypovitaminosis D and adverse clinical outcomes. **Methods:** Demographic, disease severity scores and clinical outcome data were collected in 100 consecutive patients with expected intensive care unit (ICU) admission of at least 2 days. Levels of 25-hydroxyvitamin D (25-OH-D), 1,25-dihydroxyvitamin D (1,25-(OH)₂-D), PTH and ionized calcium were measured on days 1, 3 and on day 7 or ICU discharge. **Results:** The prevalence of vitamin D insufficiency (25 nmol/L ≤ 25-OH-D ≤ 50 nmol/L) and deficiency (25-OH-

D < 25 nmol/L) were 54 and 24 %, respectively, and levels did not recover during ICU stay. Admission 25-OH-D levels correlated with 1,25-(OH)₂-D ($R = 0.61$, $p = 0.001$), Simplified Acute Physiology Score (SAPS-II) ($R = -0.3$, $p = 0.01$), Acute Physiology and Chronic Health Evaluation (APACHE-II) scores ($R = -0.2$, $p = 0.05$), but not calcium ($R = 0.16$, $p = 0.11$) or PTH ($R = -0.11$, $p = 0.31$) levels. Vitamin D deficiency was associated with fewer hospital-free days, OR 3.15 (1.18–8.43) in univariate analysis. Secondary hyperparathyroidism (PTH > 7 pmol/L) was observed in 37.5 % of hypocalcaemic and 32.5 % of vitamin D insufficient/deficient patients, and was associated with higher SAPS-II [43 (31.3–60) vs. 36 (30–43), $p = 0.03$]. **Conclusions:** Hypovitaminosis D and secondary hyperparathyroidism are highly prevalent in critically ill patients. Low vitamin D status persists during ICU stay and is associated with worse disease severity and fewer hospital-free days.

Keywords Vitamin D deficiency · Endocrine disorders · Hypocalcaemia · Secondary hyperparathyroidism

Introduction

In addition to its important endocrine role in the regulation of calcium metabolism and bone health, vitamin D is now recognized to have multiple pleiotropic functions [1]. These occur via the local production of the active form of vitamin D, 1,25-dihydroxyvitamin D, through the activity of a tissue form of 1- α -hydroxylase. This enzyme is found in a large number of mammalian tissues along with the vitamin D receptor. This has led to the recognition of important roles of vitamin D in the regulation of hormone secretion, immune function, cellular proliferation and differentiation [1, 2].

Despite the abundance of natural sunlight in Australia, a high prevalence of vitamin D deficiency has been noted, ranging from 67 to 86 % in high risk groups such as the elderly, especially if institutionalized, dark-skinned and veiled women, geriatric admissions to hospital and patients with skin cancer or malabsorption [3–6]. There is also a significant prevalence of mild vitamin D deficiency, observed in more than 20 % of healthy, younger adults, particularly during winter in the more southern latitudes of Australia [7]. Despite this knowledge, vitamin D deficiency is seldom considered and rarely replaced adequately, if at all, in critically ill patients.

Our group [8] provided the first evidence of a high prevalence of hypovitaminosis D among critically ill patients and that this was associated with higher mortality as predicted by the Simplified Acute Physiology Score (SAPS-II). Several international studies [9–13] have since replicated our findings. Despite the recognition of interplay between vitamin D, calcium and PTH, a systematic characterization of the entire PTH–vitamin D–calcium axis during critical illness has not been undertaken. It remains unclear whether vitamin D deficiency/insufficiency plays a causal role in disease severity among critically ill patients and the role of correcting vitamin D deficiency in critically ill patients has not been established.

The importance of obtaining prospective observational data on the evolution of the PTH–vitamin D–calcium axis in a diverse spectrum of critically ill patients to guide the design of further interventional studies therefore becomes imperative. The aims of the current study were to determine the prevalence of hypovitaminosis D in a wide spectrum of critical illness in adults, to evaluate changes in PTH–vitamin D–calcium axis during critical illness and to explore associations between low vitamin D levels, disease severity and clinical outcomes.

Methods

Study design

We conducted a prospective, multicentre inception cohort study of 100 consecutive patients from 3 tertiary referral

ICUs in Sydney, Australia (33° latitude) who were expected to stay in the ICU for more than 2 days. Patients on renal replacement therapy were excluded. The inception period was conducted over an 8-month period (July 2010–February 2011 to include cooler and warmer months). Human research ethics committee approval was obtained and informed consent was obtained from the patient or their surrogate.

Data collection

Baseline demographic and diagnostic data were collected on admission to ICU. Source of admission (emergency department, hospital ward or other domiciliary care facility) was recorded. Severity of illness scores collected were the Acute Physiology and Chronic Health Evaluation (APACHE-II) (range 0–71, with higher scores indicating more severe illness) [14], SAPS-II (range 0–146, with higher scores indicating more severe illness) [15] on admission and Sequential Organ Failure (SOFA) scores (range 0–20, with higher scores indicating more severe illness) on day 1, day 3 and either day 7 or discharge from ICU, whichever was earlier. (The cardiovascular, respiratory, renal, hepatic and haematological components of the SOFA score were recorded, for which scores can range from 0 to 4 for each organ system, with higher scores indicating more severe dysfunction [16].)

In addition to routine blood investigations, levels of 25-OH-D (Diasorin[®] radioimmunoassay, CV 10 %), 1,25-(OH)₂-D (Diasorin[®] radioimmunoassay, CV 10 %), intact PTH (two-site immunoassay for intact PTH, Siemens diagnostics, CV 10 %) and ionized calcium (ion-sensitive electrode–Radiometer ABL 720 blood gas analyser, CV 1.3 %) were measured on day 1 (approximately 24 h after the resuscitation phase was complete) and in the morning hours of day 3 and either at day 7 or at ICU discharge if this was prior to day 3 or 7.

None of the patients received vitamin D supplementation during their ICU stay, other than that provided in enteral or parenteral feeds (280 IU of vitamin D₃ per litre of iso-caloric enteral feed, 400 IU ergocalciferol in each 3-in-1 premix bag of parenteral feed). The first levels were sampled within 24 h of admission, prior to commencement of feeding.

As vitamin D is highly protein-bound to D-binding protein (DBP), the free (unbound) fraction of vitamin D might be a more physiologically appropriate measurement [17]. As an assay for DBP was not available at the time, a “protein correction” was performed for vitamin D. As DBP is a globulin, we “corrected” for serum globulin by dividing the 25-OH-D by the globulin level. As a result, patients with higher globulin levels (and consequently potentially lower free vitamin D levels) would have a lower “corrected” vitamin D level.

To assess the significance of an intact PTH–vitamin D–calcium axis, patients were classified as being PTH-responders or non-responders. PTH-responders were defined as patients who had an elevated PTH level (>7 pmol/L) in the presence of a low 25-OH-D (<50 nmol/L) and/or a low ionized calcium (iCa <1.15 mmol/L) on admission to ICU. Patients with impaired renal function on day 1, (eGFR <30 ml/min, $n = 17$) were excluded from the PTH analysis. Severe hepatic dysfunction was not seen in this cohort.

Outcome measures collected were ICU and hospital length of stay, ICU and hospital-free days (HFD), ICU and hospital mortality. ICU or HFDs were defined as the number of days the patient spent alive outside the ICU or hospital, respectively, in the 28-day period starting from the day of ICU admission.

Statistical analysis

Continuous variables with a normal distribution were expressed as mean (standard deviation) while all others were expressed as median (interquartile range). Coefficients of correlation between variables were calculated using Pearson's or Spearman's pairwise correlation, depending on the distribution of variables. Longitudinal changes in vitamin D metabolites and PTH were analysed using mixed models, considering both linear and polynomial models. Differences in variables between groups were tested by using unpaired Student's *t* test or Wilcoxon's ranked sum test, depending on the distribution of variables. Bivariate and multivariate logistic regression models were used to assess the associations between outcomes (i.e. mortality, ICU and HFD, PTH response) and risk factors. 25-OH-D levels were analysed as a continuous and an ordinal factor (sufficiency >50 nmol/L, insufficiency 25–50 nmol/L and deficiency <25 nmol/L) [3, 18]. All analyses were performed using R language (version 2.14.2) [19].

Results

Patient characteristics

The patient cohort studied was a mixed medical/surgical group with a spread of clinical diagnoses. Mean age was 52 ± 17 years with mean APACHE-II and SAPS-II of 21 ± 8 and 42 ± 15 , respectively (Table 1). Fifty-four patients (54 %) were admitted to the ICU in the cooler months, while the remaining were admitted in the warmer months of the year.

Vitamin D status on ICU admission

The prevalence of vitamin D insufficiency and deficiency was 55 % (95 % CI 45.2–64.3) and 24 % (95 % CI 16.7–33.2), respectively. 25-OH-D levels were undetectable

Table 1 Patient characteristics

Variable	Values ($N = 100$)
Sex (male)	65
Age (years) ^a	52 (17)
Group	
Surgical	41
Medical	59
Diagnosis at admission	
Cardiac	30
Infection/sepsis	26
Heart/lung/bone marrow transplant	21
Trauma	9
Metabolic	7
Neurological	7
Cardiac	30
25-(OH)-D (nmol/L) ^b	37 (27, 48)
1,25-(OH) ₂ -D (pmol/L) ^b	64 (44, 95)
PTH (pmol/L) ^b	5.6 (3.8, 8.0)
Ionised calcium (mmol/L) ^b	1.07 (1.01, 1.11)
Serum creatinine (μ mol/L) ^b	93 (72, 122)
Serum phosphate (mmol/L) ^b	1.15 (0.94, 1.62)
SOFA score on day 1 ^a	7 (3)
APACHE-II score ^a	21 (8)
SAPS ^a	42 (15)
ICU length of stay (days) ^b	7 (4, 14)
Hospital length of stay (days) ^b	22 (13, 32)
ICU-free days ^b	19 (11, 24)
Hospital-free days ^b	1 (0, 12)
ICU mortality	14
Hospital mortality	17

Values are number and % as $N = 100$, unless otherwise specified

^a Mean (SD)

^b Median (Q1, Q3)

(<15 nmol/L) in 8 % of the patients. Using a more stringent definition of sufficiency (>75 nmol/L) as suggested by some recent data, only 3 % of patients had sufficient levels on day 1 with the prevalence of insufficiency (50–75 nmol/L) and deficiency (<50 nmol/L) being 22 and 75 %, respectively. Characteristics of the patients are showed in Table 2. Briefly, in patients with lower vitamin D, there appeared to be a trend towards older age, higher APACHE-II and SAPS and longer lengths of stay in ICU and hospital compared to their counterparts, although this was not statistically significant. Only 17 % of the cohort had low 1,25-(OH)₂-D levels (<40 pmol/L) on day 1.

There was a trend towards lower vitamin D levels in patients admitted in cooler months compared to those admitted in warmer months (35.3 ± 16.3 vs. 41.9 ± 18.6 nmol/L, $p = 0.06$). Significantly lower levels were seen in patients who spent at least 7 days in hospital or an institution prior to ICU admission (32.0 ± 21.2 vs. 40.1 ± 16.9 nmol/L, $p = 0.01$).

Relationship between parameters of the vitamin D axis

Admission levels of 25-OH-D were highly correlated with 1,25-(OH)₂-D ($R = 0.61$, $p = 0.001$) but there was no

Table 2 Participant characteristics, stratified by vitamin D status

Variable	Sufficient (n = 21)	Insufficient (n = 55)	Deficient (n = 24)
Age (years) ^a	48 (17)	52 (17)	56 (17)
Sex (male) ^b	16 (72.7)	40 (72.7)	9 (40.9)
SOFA score on day	6 (4)	6 (3)	9 (4)
APACHE-II score ^c	18 (6)	21 (8)	23 (8)
SAPS	37 (13)	41 (16)	51 (14)
ICU length of stay (days) ^{d,e}	4 (3, 10)	7 (4, 15)	12 (2, 14)
Hospital length of stay (days) ^{d,f}	12 (9, 23)	24 (15, 32)	24 (3, 37)
ICU-free days ^d	24 (11, 25)	20 (13, 24)	14 (0, 19)
Hospital-free days ^d	13 (0, 19)	0 (0, 11)	0 (0, 8)
ICU mortality ^b	4 (18.2)	4 (7.2)	6 (27.2)
Hospital mortality ^b	5 (22.7)	6 (10.9)	6 (27.3)

Values are mean (SD), unless otherwise specified

Vitamin D status: 25-OH-D >50 nmol/L, sufficient; 25–50 nmol/L, insufficient; <25 nmol/L, deficient

Trend analysis: ^a *p* value = 0.5076; ^b *n* (%); ^c *p* value = 0.1956; ^d Median (Q1, Q3); ^e *p* value = 0.1836; ^f *p* value = 0.0871

Table 3 Correlation among 25-OH-D and other parameters at baseline

	Age (years)	SAPS	APACHE-II	SOFA (day 1)	25-OH-D ^a	1,25-(OH) ₂ -D ^a	PTH ^a	Calcium ^a
Age (years)		0.23	0.13	0.23	-0.22	-0.30	0.06	0.10
SAPS	(0.02)*		0.75	0.25	-0.27	-0.19	0.16	-0.11
APACHE-II	(0.22)	(0.00)*		0.27	-0.20	-0.15	0.12	-0.12
SOFA (day 1)	(0.02)*	(0.02)*	(0.01)*		-0.20	-0.37	-0.18	-0.22
25-OH-D ^a	(0.03)*	(0.01)*	(0.05)	(0.05)		0.61	-0.11	0.16
1,25-(OH) ₂ -D ^a	(0.00)*	(0.07)	(0.16)	(0.00)*	(0.00)*		-0.02	0.07
PTH ^a	(0.57)	(0.15)	(0.28)	(0.10)	(0.31)	(0.87)		-0.19
Calcium ^a	(0.32)	(0.31)	(0.25)	(0.03)*	(0.11)	(0.51)	(0.09)	

Values are correlation coefficient (*p* value)

* *p* < 0.05

^a log transformation

correlation between 25-OH-D and calcium ($R = 0.16$, $p = 0.11$) or PTH ($R = -0.11$, $p = 0.31$) levels (Table 3).

PTH–vitamin D–calcium axis

The prevalence of ionized hypocalcaemia (calcium <1.15 mmol/L) was 83 % at admission to ICU.

Secondary hyperparathyroidism (as defined by PTH >7 pmol/L) was seen in 37.5 % of hypocalcaemic and 32.5 % of vitamin D insufficient/deficient patients. PTH-responders were found to have higher SAPS-II [43 (31.3–60) vs. 36 (30–43), $p = 0.03$] on admission to ICU, but there was no mortality difference between PTH-responders and non-responders.

Variation during critical illness

There was no significant difference in 25-OH-D or 1,25-(OH)₂-D levels between days 1, 3 and 7 of ICU stay (Table 3). There was, however, a significant drop in PTH levels and rise in calcium levels between days 1 and 7 (Table 4).

Table 4 Levels during ICU stay

	Day 1	Day 3	Day 7	<i>p</i> value*
25-OH-D (nmol/L)	38.8 (17.8)	37.7 (16.1)	41.3 (20.0)	0.17
1,25-(OH) ₂ -D (pmol/L)	76.4 (48.9)	86.7 (55.5)	100.3 (84.2)	0.06
PTH (pmol/L)	6.7 (4.1)	8.5 (13.1)	6.3 (6.2)	0.02
Calcium (mmol/L)	1.07 (0.14)	1.11 (0.08)	1.14 (0.07)	<0.0001


Values are mean (SD)

* *F* test, repeated measures ANOVA with log-transformed values

Associations with severity of illness and outcome

Admission 25-OH-D levels showed a modest correlation with the SAPS-II ($R = -0.3$, $p = 0.01$) and APACHE-II scores ($R = -0.2$, $p = 0.05$) (Fig. 1). On the other hand there was no relationship between admission levels of calcium, PTH or 1,25-(OH)₂-D and SAPS-II or APACHE-II scores. However, there was a significant correlation between admission calcium levels and SOFA ($R = -0.22$, $p = 0.03$).

Fig. 1 Correlation between vitamin D levels on day 1 and SAPS and APACHE-II scores



When a globulin concentration correction was performed for 25-OH-D, the correlation was somewhat strengthened ($R = -0.32$, $p < 0.0001$ and $R = -0.24$, $p = 0.02$ for SAPS-II and APACHE-II, respectively).

Higher SAPS-II and APACHE-II scores in this cohort indicated increased risk of mortality OR 1.77 (1.01–3.09) and 3.3 (1.41–7.7), respectively. There was no relationship between 25-OH-D levels or any of the other parameters and mortality in this cohort (Supplementary Table 1).

However, vitamin D deficiency (<25 nmol/L) was associated with significantly fewer hospital-free days, OR 3.15 (1.18–8.43) with a similar, albeit non-significant, association with vitamin D insufficiency, OR 2.30 (0.86–6.15). None of the other biochemical parameters were associated with mortality, hospital or ICU-free days (Supplementary Table 1).

Multivariate analyses were constructed using two models including age, SAPS, 25-OH-D and PTH in one model and age, APACHE-II, 25-OH-D and PTH in the second model (Supplementary Table 2). Age and APACHE-II were the only independent predictors of mortality.

Discussion

Principal findings

This prospective study characterizes expressions of the vitamin D, calcium and PTH status in adult patients with diverse diagnoses during the course of critical illness. It confirms a high prevalence of hypovitaminosis D, with vitamin D sufficiency observed in only 22 % of patients. None of these patients were on vitamin D supplementation in hospital prior to ICU admission. Data prior to hospitalization were not collected in this study, but were previously collected by our group in a point prevalence study in 2010. Of 506 ICU patients studied, only 2 % were on oral vitamin D supplements of 400–600 Units/day. In this context, we consider vitamin D supplements

on admission unlikely to contribute to our current study findings.

Secondary hyperparathyroidism was seen in a third of vitamin D insufficient/deficient patients and was associated with worse disease severity scores; however, in this cohort it was not associated with mortality. Vitamin D deficient patients had fewer hospital-free days, compared to those who were sufficient. Collectively, the current findings reveal profound changes in the PTH–vitamin D–calcium axis in critical illness that appear to be associated with worse disease severity and fewer hospital-free days.

Comparison with other studies

We conducted an initial dedicated evaluation of vitamin D status in critically ill patients in 2009 which revealed a previously under-recognized high prevalence of vitamin D insufficiency/deficiency in ICU patients [8]. Only 7 % of patients were sufficient and predicted mortality was three times higher in deficient patients. Subsequently other studies confirmed a similarly high prevalence [9–13]. Low vitamin D state was associated with worse outcomes in all but one study [13].

There has been concern about the accuracy of vitamin D measurements in critical illness, prompted by a recent study revealing a 35 % reduction in 25-OH-D concentrations secondary to 3-L fluid loading in patients undergoing cardiopulmonary bypass [20]. The applicability of this finding to current published reports is uncertain. It is highly unlikely that the low vitamin D levels observed are entirely due to a dilutional effect of intravenous volume resuscitation. Up to 20 % of patients had undetectable levels [8, 10] and the current study showed persistently low concentrations over 7 days, thus arguing against an acute dilutional effect. Another study [21] demonstrated variability in 25-OH-D levels over a 24-h period. The authors therefore recommend more than one measurement to more accurately determine vitamin D status, as has been undertaken in the current study.

Strengths and weaknesses

The study population was taken as a consecutive collection of critically ill adults in three tertiary centres, therefore demonstrating that vitamin D deficient states in critically ill patients are not the result of selection bias. Metabolites of vitamin D, PTH and ionized calcium were sampled at three time periods per patient, thereby providing information about levels during the hyper acute, acute and more chronic or recovery phases of critical illness. However, owing to the heterogeneity of the patient population, the numbers of patients per diagnostic group were small, making it difficult to draw conclusions about particular patient subgroups. As patients had an overall low hospital mortality rate, the relationship between vitamin D deficiency and mortality could not be determined. Therefore surrogate measures such as ICU- and hospital-free days had to be utilized. Although the association of vitamin D deficiency with severity of illness and hospital length of stay has been demonstrated, a causative link cannot be made.

Clinical implications

Causes of low vitamin D states are multifactorial in critically ill patients, stemming from limited sunlight exposure, poor intake and vitamin D wastage secondary to loss of transport proteins [22]. D-binding protein (DBP) is the major carrier protein for circulating 25-OH-D. DBP concentrations have been found to be 30 % lower in critically ill patients, especially among those with sepsis [23, 24], trauma [25] and renal failure [26, 27]. Although DBP measurements were not available during the course of the current study, globulin was used as a surrogate marker. This 'corrected' protein-bound vitamin D was more strongly correlated with illness severity than the uncorrected level, highlighting the need to consider this aspect in future studies.

It is well known that vitamin D plays a critical role in the calcium–PTH axis. However, there are a paucity of data in the systematic characterization of the relationship between vitamin D, calcium and PTH in critical illness. Hypocalcaemia is common in critically ill patients [28, 29], leading to secondary hyperparathyroidism, as observed in over a third of our cohort (37.5 %). This, however, does not correct calcium malabsorption from the intestine, which appears to require both calcitriol and 25-OH-D. Furthermore, calcitriol produced at tissue level, which is responsible for the non-skeletal functions of vitamin D, cannot be measured clinically. We speculate that the rise in PTH heightens the conversion of 25-OH-D to 1,25-(OH)₂-D, thereby maintaining 1,25-(OH)₂-D levels, but stimulating bone resorption and intestinal calcium absorption, thus maintaining calcium homeostasis. However, secondary hyperparathyroidism may persist in these

patients because of tissue level vitamin D deficiency [30]. Therefore, the lack of a PTH response may in fact confer better tissue vitamin D utilization, indicative of tissue vitamin D sufficiency, and therefore be associated with better recovery as evidenced by lower severity of illness scores seen in our cohort of PTH non-responders. In other words, inconsistent correlative data between low circulating vitamin D levels and disease outcome in the literature [31] may reflect the imprecise portrayal of tissue vitamin D status by circulating levels. This is consistent with a study of PTH response in the elderly, which showed that the absence of secondary hyperparathyroidism in the presence of hypovitaminosis D was associated with longer survival [32].

These data and complex health outcome relationships suggest the need for interpreting low vitamin D status in critically ill patients in conjunction with parathyroid status.

Future directions

The main question arising from the current study is whether vitamin D deficiency is causally linked to adverse outcomes. While currently no data support a therapeutic role of vitamin D in critical illness, the association of low vitamin D status with severity of illness and several surrogate markers of outcome suggests that further interventional studies of vitamin D supplementation are worthwhile. Our findings provide novel observational data revealing the complex interplay between low vitamin D states and parathyroid status, which should assist with the design of intervention studies.

Although vitamin D has a wide safety margin and therefore a low potential for toxicity, vitamin D supplementation in critical illness may not result in improved outcome. Previous experiences with manipulation to correct endocrine perturbations in critical illness have shown inconsistent results, and in some cases have resulted in adverse outcomes. Examples include growth hormone supplementation [33], tight glycemic control [34] and steroid supplementation in adrenal insufficiency [35]. By contrast with these hormonal variations, the serum levels of 25-OH-D are not thought to be under any humoral control. Rather, low vitamin D levels in critical illness could represent a longer duration of underlying illness or high utilization during acute illness. Several small studies have evaluated the safety and efficacy of high dose oral vitamin D in ICU patients [9, 36].

Conclusion

In summary, low vitamin D levels are highly prevalent in critically adults with 78 % of patients having either insufficient or deficient levels. 25-OH-D and 1,25-(OH)₂-

D levels did not vary significantly during ICU stay. Low levels of vitamin D and hyperparathyroidism were associated with increased severity of illness on ICU admission. Furthermore, low vitamin D levels were associated with fewer hospital-free days in univariate but not multivariate analyses after accounting for severity of illness. While it remains to be determined whether low vitamin D status is causally implicated in the pathogenesis of critical illness co-morbidities, findings from this

study highlight the imperative for future evaluation of dosing and safety regimens followed by randomized control trials of vitamin D in the ICU.

Acknowledgments We gratefully acknowledge the contribution of David Gattas, Dorrilyn Rajabhandari, Heidi Buhr (Royal Prince Alfred Hospital, Sydney), Manoj Saxena, Rebecca Sidoli and Deborah Inskip (St George Hospital, Sydney) to patient enrolment and data collection.

References

- Holick MF (2007) Vitamin D deficiency. *N Engl J Med* 357:266–281
- Bikle D (2009) Nonclassic actions of vitamin D. *J Clin Endocrinol Metab* 94:26–34
- Diamond TH, Eisman JA, Mason RS, Nowson CA, Pasco JA, Sambrook PN, Wark JD, Working Group of the Australian and New Zealand Bone and Mineral Society, Endocrine Society of Australia, Osteoporosis Australia (2005) Vitamin D and adult bone health in Australia and New Zealand: a position statement. *Med J Aust* 182:281–285
- Grover SR, Morley R (2001) Vitamin D deficiency in veiled or dark-skinned pregnant women. *Med J Aust* 175:251–252
- Inderjeeth CA, Nicklason F, Al-Lahham Y, Greenaway TM, Jones G, Parameswaran VV, David R (2000) Vitamin D deficiency and secondary hyperparathyroidism: clinical and biochemical associations in older non-institutionalised Southern Tasmanians. *Aust N Z J Med* 30:209–214
- Sambrook PN, Cameron ID, Cumming RG, Lord SR, Schwarz JM, Trube A, March LM (2002) Vitamin D deficiency is common in frail institutionalised older people in northern Sydney. *Med J Aust* 176:560
- Pasco JA, Henry MJ, Nicholson GC, Sanders KM, Kotowicz MA (2001) Vitamin D status of women in the Geelong osteoporosis study: association with diet and casual exposure to sunlight. *Med J Aust* 175:401–405
- Lee P, Eisman JA, Center JR (2009) Vitamin D deficiency in critically ill patients. *N Engl J Med* 360:1912–1914
- Mata-Granados JM, Vargas-Vassero J, Ferreira-Vera C, Luque de Castro MD, Pavon RG, Quesada Gomez JM (2010) Evaluation of vitamin D endocrine system (VDES) status and response to treatment of patients in intensive care units (ICUs) using an on-line SPE-LC-MS/MS method. *J Steroid Biochem Mol Biol* 121:452–455
- Lucidarme O, Messai E, Mazzone T, Arcade M, du Cheyron D (2010) Incidence and risk factors of vitamin D deficiency in critically ill patients: results from a prospective observational study. *Intensive Care Med* 36:1609–1611
- McKinney JD, Bailey BA, Garrett LH, Peiris P, Manning T, Peiris AN (2011) Relationship between vitamin D status and ICU outcomes in veterans. *J Am Med Dir Assoc* 12:208–211
- Braun A, Chang D, Mahadevappa K, Gibbons FK, Liu Y, Giovannucci E, Christopher KB (2011) Association of low serum 25-hydroxyvitamin D levels and mortality in the critically ill. *Crit Care Med* 39:671–677
- Cecchi A, Bonizzoli M, Douar S, Mangini M, Paladini S, Gazzini B, Degl'Innocenti S, Linden M, Zagli G, Peris A (2011) Vitamin D deficiency in septic patients at ICU admission is not a mortality predictor. *Minerva Anestesiol* 77:1184–1189
- Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE (1981) APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. *Crit Care Med* 9:591–597
- Le Gall JR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. *JAMA* 270:2957–2963
- Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European society of intensive care medicine. *Intensive Care Med* 22:707–710
- Bikle DD, Gee E, Halloran B, Kowalski MA, Ryzen E, Haddad JG (1986) Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. *J Clin Endocrinol Metab* 63:954–959
- Holick MF (2009) Vitamin D status: measurement, interpretation, and clinical application. *Ann Epidemiol* 19:73–78
- R Development Core Team (2011) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, <http://www.R-project.org/>
- Krishnan A, Ochola J, Mundy J, Jones M, Kruger P, Duncan E, Venkatesh B (2010) Acute fluid shifts influence the assessment of serum vitamin D status in critically ill patients. *Crit Care* 14:R216
- Venkatesh B, Davidson B, Robinson K, Pascoe R, Appleton C, Jones M (2012) Do random estimations of vitamin D₃ and parathyroid hormone reflect the 24-h profile in the critically ill? *Intensive Care Med* 38:177–179
- Lee P (2011) Vitamin D metabolism and deficiency in critical illness. *Best Pract Res Clin Endocrinol Metab* 25:769–781
- Van den Berghe G, Van Roosbroeck D, Vanhove P, Wouters PJ, De Pourcq L, Bouillon R (2003) Bone turnover in prolonged critical illness: effect of vitamin D. *J Clin Endocrinol Metab* 88:4623–4632
- Jeng L, Yamshchikov AV, Judd SE, Blumberg HM, Martin GS, Ziegler TR, Tangpricha V (2009) Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. *J Transl Med* 7:28
- Dahl B, Schiødt FV, Ott P, Wiens F, Lee WM, Balko J, O'Keefe GE (2003) Plasma concentration of Gc-globulin is associated with organ dysfunction and sepsis after injury. *Crit Care Med* 31:152–156

-
26. Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, Herz J, Melsen F, Christensen EI, Willnow TE (1999) An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D₃. *Cell* 96:507–515
 27. Thraillkill KM, Jo CH, Cockrell GE, Moreau CS, Fowlkes JL (2011) Enhanced excretion of vitamin D binding protein in type 1 diabetes: a role in vitamin D deficiency? *J Clin Endocrinol Metab* 96:142–149
 28. Hastbacka J, Pettila V (2003) Prevalence and predictive value of ionized hypocalcemia among critically ill patients. *Acta Anaesthesiol Scand* 47:1264–1269
 29. Zaloga GP, Chernow B (1986) Hypocalcemia in critical illness. *JAMA* 256:1924–1929
 30. Lee P, Nair P, Eisman JA, Center JR (2009) Vitamin D deficiency in the intensive care unit: an invisible accomplice to morbidity and mortality? *Intensive Care Med* 35:2028–2032
 31. Thacher TD, Clarke BL (2011) Vitamin D insufficiency. *Mayo Clin Proc* 86:50–60
 32. Chen JS, Sambrook PN, March L, Cameron ID, Cumming RG, Simpson JM, Seibel MJ (2008) Hypovitaminosis D and parathyroid hormone response in the elderly: effects on bone turnover and mortality. *Clin Endocrinol (Oxf)* 68:290–298
 33. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, Hinds CJ (1999) Increased mortality associated with growth hormone treatment in critically ill adults. *N Engl J Med* 341:785–792
 34. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hebert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ (2009) Intensive versus conventional glucose control in critically ill patients. *N Engl J Med* 360:1283–1297
 35. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J (2008) Hydrocortisone therapy for patients with septic shock. *N Engl J Med* 358:111–124
 36. Amrein K, Sourij H, Wagner G, Holl A, Pieber TR, Smolle KH, Stojakovic T, Schnedl C, Dobnig H (2011) Short-term effects of high-dose oral vitamin D₃ in critically ill vitamin D deficient patients: a randomized, double-blind, placebo-controlled pilot study. *Crit Care* 15:R104